Quantum Genomics (PAR: ALQGC)

Currency in EUR

Last close As at 07/06/2023


0.00 (0.00%)

Market capitalisation


Quantum Genomics is a Paris-based biotechnology company focused on addressing unmet medical needs.

The global market for cardiovascular drugs is considerable; in 2021 the market for hypertension drugs alone was estimated to be worth c US$13bn. Quantum Genomics has already secured seven licensing deals worldwide (worth up to c US$123m) but has not yet signed an agreement in the key US or EU5 regions. We view the signing of a licensing agreement in these regions as key to maximising the commercial impact of the asset.



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Benoît Gueugnon


  • Jean-Philippe Milon


  • Lionel Ségard

    Founder & Chairman

Balance Sheet

Forecast net debt (€m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.7 10.9 (91.1)
Relative 9.7 13.8 (91.8)
52 week high/low €4.0/€0.1


Following the announcement that results from the Phase III FRESH study, investigating the use of firibastat in treatment-resistant hypertension (TRH) were non-significant versus placebo, Quantum Genomics has terminated a second, longer-term Phase III trial (REFRESH) in TRH and will stop the development of firibastat in cardiology. The company estimates it will have c €11m after the full discontinuation of cardiology development with which to pursue new opportunities to develop new assets. Our estimates and valuation for Quantum Genomics are under review.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2020A 4.0 (13.1) (14.7) (72.0) N/A N/A
2021A 6.2 (14.9) (15.4) (58.0) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free